LENZ Therapeutics (LENZ) Cash from Investing Activities Growth (3y) (2023 - 2026)

LENZ Therapeutics (LENZ) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -29.84%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 38.24%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -22.09%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 LENZ Therapeutics 177.61 Mn -80.77 Mn 825,000.00 1,668.25%

Historic Data

Download Data
DateValue
Mar 31, 2026 1,668.25%
Dec 31, 2025 -105.20%
Sep 30, 2025 -47.96%
Jun 30, 2025 83.26%
Mar 31, 2025 28.27%
Dec 31, 2024 -129.53%
Sep 30, 2024 -157.70%
Jun 30, 2024 -405.21%
Mar 31, 2024 273.25%
Dec 31, 2023 199.23%
Sep 30, 2023 -218.58%